Tetragon Partners GP Ltd
Position in AMLX — Amylyx Pharmaceuticals, Inc.
CIK 1515070
GRAND CAYMAN, E9
Position in AMLX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$5,350,750
+$932,260 QoQ
Shares Held
297,926
-6.3% QoQ
Ownership
0.267%
of shares outstanding
% of Portfolio
0.87%
of 13F equity value
Holder Rank
#53
of 207 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in AMLX Over Time
Shares Held
Position Value (USD)
Derivatives in AMLX
reported options exposure · as of Jun 30, 2026CallValue
$152,660
CallShares
8,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Tetragon Partners GP Ltd holds $15,305,649 across 2 Drug Manufacturers - Specialty & Generic names. AMLX ranks #2 (35.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALKS |
Alkermes plc.
|
189,979 | $9,954,899 | |
| 2 | AMLX |
Amylyx Pharmaceuticals, Inc.
This page
|
297,926 | $5,350,750 |
All Filings in AMLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $152,660 | 8,500 | Call | Defined | 2026-08-13 | |
| 2026-06-30 | $5,350,750 | 297,926 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $4,418,490 | 317,877 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $3,295,762 | 272,828 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $3,509,508 | 258,242 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,402,187 | 218,750 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||